Sudhir K. Rai

Dr.Sudhir Kumar Rai obtained his Ph.D. in Molecular Biology and Biotechnology from Tezpur Central University, INDIA. Having more than 10 years of research experience from the Top USA and French research Institutions with working experience in diverse lab environments made Dr.Rai adapt and contribute ASAP to any US Based Biotech/Pharma industry sector. In the span of 10 years, Dr.Rai build-up key qualities like resolving major scientific problems, making critical decisions to push the experiments, enhances very effective communication within the team as well as within the organization. (Therapeutic Enzyme formulation from the microbial resource of Northeastern-India region) Having proven experience in pharmaceutical/Biotech grade therapeutic enzyme formulation by a combination of downstream and upstream platforms such as protein purification and characterization using biochemical assay (More than 20 peer-reviewed first author publications published in Elsevier and SpringerLink journals). Transposon Biology (Tf1-Long Terminal Repeat) and pathogenic DNA repeat expansion(G4C2/C4G2) Biology modeling into Schizosaccharomyces pombe) Having proven experience in handling large Schizosaccharomyces pombe (fission yeast) Bioneer deletion 3000 Knockout libraries with full digital record and deletion strain maintenance of a collection of 12000 independent strains along with key scientific skills such as mutant strain construction and micromanipulation, Biochemical characterization, southern and western blot, gene complementation, gene cloning, CRISPR-Cas9 knockout version as CRISPR-dead Cas9 version, Imaging-using GFP tag/ mCherry tag, nucleus staining by DAPI, cell cycle study, genetic, Next-generation sequencing, and molecular biology (Published PLOS GENETICS & Springerlink journals). Cancer Metabolism (metabolomic Profiling of Pheochromocytoma-Succinate Dehydrogenase mutation subunit-B mutation). Having proven experience in handling patient-derived succinate dehydrogenase subunit-B/C/D mutant Pheochromocytoma/Paraganglioma cell line and metabolomics in a stable knockout cell line of succinate dehydrogenase subunit-B along with polyamine inhibitors treatment under invitro and invivo studies using various molecular and cancer biology techniques such as qRT-PCR, Western blot, colony-forming assay, CRISPR-Cas9 knockout cell line construction, Xenograft model (Published as a first author peer-reviewed publication in Elsevier journal). During my off duty, I love to meet and talk with new people and learn more about them.